Expertise in
28
conditions

Dr. Seth B. Forman

Dermatology
15416 N Florida Ave, 
Tampa, FL 
Expertise in
28
conditions
15416 N Florida Ave, 
Tampa, FL 

Overview

Seth Forman is a Dermatologist practicing medicine in Tampa, Florida.

Dr. Forman is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Atopic Dermatitis, Hidradenitis Suppurativa, Plaque Psoriasis, and Psoriasis.

Dr. Forman is board certified in American Board Of Dermatology. He is actively involved in clinical research, co-authoring 43 peer reviewed articles and participating in 47 clinical trials.

Specialties

Dermatology

Licenses

Dermatology in FL

Board Certifications

American Board Of Dermatology

Fellowships

Geisinger Medical Center , Dermatology

Hospital Affiliations

AdventHealth Tampa

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Florida Blue
  • EPO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MetLife
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 21 Less Insurance Carriers -

Locations

Phdermatology
15416 N Florida Ave, Tampa, FL 33613

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

27 Clinical Trials

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: April 16, 2026
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 2/Phase 3
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: April 07, 2026
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: November 05, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Phase Ib, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study of the Clinical Effect, Safety and Tolerability of a Single Intravenous Infusion of GSK1070806 in Moderate to Severe Atopic Dermatitis Patients
A Phase Ib, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study of the Clinical Effect, Safety and Tolerability of a Single Intravenous Infusion of GSK1070806 in Moderate to Severe Atopic Dermatitis Patients
Enrollment Status: Completed
Publish Date: August 28, 2025
Intervention Type: Drug
Study Drug: GSK1070806
Study Phase: Phase 1
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Trial to Evaluate the Efficacy and Safety of ASLAN004 in Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Trial to Evaluate the Efficacy and Safety of ASLAN004 in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: April 26, 2024
Intervention Type: Drug, Biological
Study Drug: ASLAN004
Study Phase: Phase 2
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Psoriasis
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Psoriasis
Enrollment Status: Completed
Publish Date: February 20, 2024
Intervention Type: Drug
Study Drug: LY3471851
Study Phase: Phase 1
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Atopic Dermatitis
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: February 20, 2024
Intervention Type: Drug
Study Drug: NKTR-358
Study Phase: Phase 1
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drug: Lebrikizumab
Study Phase: Phase 3
Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 2 (TRuE AD2) - A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 2 (TRuE AD2) - A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 28, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
Enrollment Status: Terminated
Publish Date: September 18, 2023
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

43 Total Publications

Roflumilast foam versus vehicle foam for seborrheic dermatitis (STRATUM clinical study): a plain language summary.
Roflumilast foam versus vehicle foam for seborrheic dermatitis (STRATUM clinical study): a plain language summary.
Journal: The Journal of dermatological treatment
Published: June 11, 2026
Similar Doctors
Expertise in
17
conditions
Expertise in
17
conditions
Referral may be required
Before you request

H Lee Moffitt Cancer Center And Research

10920 McKinley Dr, 
Tampa, FL 
 (4.1 miles away)
813-745-8414
Languages Spoken:
English, German, Spanish
See accepted insurances
Accepting New Patients

Lucia Seminario-Vidal is a Dermatologist practicing medicine in Tampa, Florida. Dr. Seminario-Vidal is highly rated in 17 conditions, according to our data. Her clinical expertise encompasses Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides, T-Cell Lymphoma, Erythema Multiforme, and Bone Marrow Aspiration. Dr. Seminario-Vidal is currently accepting new patients.

Expertise in
27
conditions
Expertise in
27
conditions
Referral may be required
Before you request

Midstate Skin Institute LLC

17653 N Dale Mabry Hwy, 
Lutz, FL 
 (3.3 miles away)
352-512-0092
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Ashley Cauthen is a Dermatologist practicing medicine in Lutz, Florida. Dr. Cauthen is highly rated in 27 conditions, according to our data. Her clinical expertise encompasses Sunburn, Plaque Psoriasis, Telangiectasia, and Spider Angioma. Dr. Cauthen is board certified in American Board Of Dermatology. Dr. Cauthen is currently accepting new patients.

Expertise in
37
conditions
Dr. David A. Lam
Dermatology
Expertise in
37
conditions
Dr. David A. Lam
Dermatology
Referral required
Before you request

Academic Alliance In Dermatology

1005 E Boyer St, 
Tarpon Springs, FL 
 (17.3 miles away)
727-934-7638
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

David Lam is a Dermatologist practicing medicine in Tarpon Springs, Florida. Dr. Lam is highly rated in 37 conditions, according to our data. His clinical expertise encompasses Kaposiform Hemangioendothelioma, Fetal Cystic Hygroma, Cerebral Cavernous Malformation, and Tufted Angioma. Dr. Lam is board certified in American Board Of Dermatology. Dr. Lam is currently accepting new patients.

Frequently Asked Questions about Dr. Seth B. Forman

How do I make an appointment with Dr. Seth B. Forman?

You can book an appointment with Dr. Seth B. Forman by calling their office at 813-960-2400. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Seth B. Forman a top-rated expert for Atopic Dermatitis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Seth B. Forman is classified as an Elite expert for Atopic Dermatitis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Seth B. Forman specialize in?

While Dr. Seth B. Forman is a Dermatology, they have specific expertise in Atopic Dermatitis, Hidradenitis Suppurativa, and Plaque Psoriasis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Dermatology.

Does Dr. Seth B. Forman participate in research or clinical trials?

Yes. Dr. Seth B. Forman has published 43 articles and abstracts on conditions like Atopic Dermatitis. You can view a list of Dr. Seth B. Forman's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Seth B. Forman accept my insurance?

Dr. Seth B. Forman accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 813-960-2400 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Forman's expertise for a condition
ConditionClose
View All 23 Advanced Conditions
View All 41 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile